FD&C Act Section 505(j) - Abbreviated New Drug Applications

What it says

A generic drug may be approved through an abbreviated application that relies on demonstrating bioequivalence to an already-approved reference listed drug, rather than requiring independent clinical safety and efficacy data, provided the generic product has the same active ingredient, strength, dosage form and route of administration.

Paraphrased for plain-language clarity. Always verify against the current published regulation text.

What it means in practice

• This abbreviated pathway relates specifically to the clinical and bioequivalence showing, a generic manufacturer must still independently satisfy the full CGMP manufacturing requirements under 21 CFR Part 211, the abbreviated nature of the application does not extend to manufacturing quality obligations.
• Bioequivalence data supporting an abbreviated application depends on validated bioanalytical methods, connecting this pathway closely to the principles in ICH M10.
• A manufacturing process or formulation difference between the generic product and its reference listed drug, even where bioequivalence is demonstrated, must still be justified and is scrutinized for its potential impact on that bioequivalence over the product's life.

What FDA inspectors look for

• Whether the generic manufacturer's own CGMP systems are fully established, independent of simply referencing the brand product's manufacturing history.
• Whether bioequivalence data supporting the application was generated using validated bioanalytical methods appropriate to the product.
• Whether post-approval manufacturing changes were evaluated for their potential impact on the product's established bioequivalence to the reference listed drug.

Related regulations